Metronidazol B. Braun (Metronidazole)

Metronidazole is reduced inside anaerobic microorganisms to form nitro radicals. These reactive species damage DNA and inhibit nucleic acid synthesis, leading to bacterial or protozoal cell death. The drug’s selective activation in low‑oxygen environments makes it effective against anaerobes while sparing aerobic cells.

The specific dose and infusion rate of Metronidazol B. Braun are determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and other clinical factors. Healthcare providers follow local guidelines and adjust therapy as needed.

Safety data for metronidazole in pregnancy are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit justifies the risk to the fetus. Breastfeeding mothers should consult a physician, as metronidazole can be excreted in breast milk.

To request Metronidazol B. Braun, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Metronidazol B. Braun (metronidazole) is a nitroimidazole with strong activity against obligate anaerobes and certain protozoa, offering excellent tissue penetration, including the central nervous system. Compared with beta‑lactam/β‑lactamase inhibitor combinations, metronidazole provides a narrower spectrum focused on anaerobes, often with fewer allergic reactions but with a distinct side‑effect profile such as a disulfiram‑like reaction with alcohol.

Metronidazol B. Braun should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if the container is damaged or the solution appears discolored.

Metronidazol B. Braun is administered intravenously by slow infusion into a vein, usually diluted in compatible IV fluids as directed by the prescriber. Administration should be performed by qualified healthcare personnel in a clinical setting, following aseptic technique and monitoring for any infusion‑related reactions.

Serious risks include seizures, peripheral neuropathy, severe allergic reactions (including anaphylaxis), Stevens‑Johnson syndrome, liver toxicity, and hematologic abnormalities such as agranulocytosis. Patients should be monitored for neurological symptoms, skin changes, liver function abnormalities, and signs of infection or bleeding.

Metronidazol B. Braun is contraindicated in patients with a known hypersensitivity to metronidazole or other nitroimidazole derivatives. Caution is advised for individuals with severe hepatic or renal impairment, those in the first trimester of pregnancy, and patients with a history of seizures or peripheral neuropathy unless benefits outweigh risks.